KRAS and non-small cell lung carcinoma: The advent of immune checkpoint inhibitors (ICIs) and ICI combinations with chemotherapy has led to many multi-variate analyses analyzing the prognostic effect of various KRAS mutations in metastatic NSCLC and the predictive effects of the newer treatments.